MARKET

DYN

DYN

Dyne Therapeutics, Inc.
NASDAQ
20.33
+0.07
+0.35%
After Hours: 20.34 +0.01 +0.05% 16:52 06/24 EDT
OPEN
20.38
PREV CLOSE
20.26
HIGH
21.13
LOW
20.27
VOLUME
2.19M
TURNOVER
--
52 WEEK HIGH
25.00
52 WEEK LOW
8.06
MARKET CAP
3.36B
P/E (TTM)
-6.3097
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Dyne Therapeutics (DYN), Argenx Se (ARGX)
TipRanks · 12h ago
Dyne Therapeutics (DYN) Is Up 12.1% After Expanding Debt Facility And Adding Veteran Biotech Director
Simply Wall St · 21h ago
Dyne Therapeutics director Barry E. Greene files initial beneficial ownership statement
PUBT · 1d ago
Dyne Therapeutics Appoints Barry Greene To Board Of Directors
NASDAQ · 1d ago
Dyne Therapeutics Names Barry Greene Independent Board Director
TipRanks · 1d ago
Dyne Therapeutics director Dirk Kersten disposes of 84,355 common shares worth $1.7 million
PUBT · 2d ago
Dyne Therapeutics appoints former Sage CEO Barry Greene to board
PUBT · 2d ago
DYNE THERAPEUTICS APPOINTS BARRY GREENE TO BOARD OF DIRECTORS
Reuters · 2d ago
More
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.

Webull offers Dyne Therapeutics, Inc stock information, including NASDAQ: DYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DYN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DYN stock methods without spending real money on the virtual paper trading platform.